Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Journal Articles Refereed uri icon

Overview

Authors

  • Authorship

    • KANTARJIAN HM
    • MEHTA B
    • FRANKLIN J
    • GIAGOUNIDIS A
    • FENAUX P
    • SEKERES MA
    • PROF Jeffrey Szer
    • PLATZBECKER U
    • KUENDGEN A
    • GAIDANO G
    • WIKTOR-JEDRZEJCZAK W
    • CARPENTER N

Published in

  • The Lancet Haematology

Time

Date/time value

  • 2018

Identity

Digital Object Identifier (DOI)

  • 10.1016/S2352-3026(18)30016-4

Additional Document Info

Parent Title

  • Lancet Haematol

Volume

  • 5

Issue

  • 3

Publisher

  • The Lancet Publishing Group